Eribulin in combination with HER2-targeted antibodies for successful treatment of metastatic salivary duct carcinoma: A report of two cases

Oral Oncol. 2021 Sep:120:105287. doi: 10.1016/j.oraloncology.2021.105287. Epub 2021 Apr 13.

Authors

Affiliations

¹ Department of Hematology, Sapporo Kiyota Hospital, Japan. Electronic address: [email protected].
² Department of Hematology, Sapporo Kiyota Hospital, Japan.
³ Department of Internal Medicine, Sapporo Kiyota Hospital, Japan.
⁴ Department of Medical Oncology, Sapporo Medical University, Japan.
⁵ Department of Surgical Pathology, Sapporo Medical University, Japan.

PMID: 33858766
DOI: 10.1016/j.oraloncology.2021.105287

No abstract available

Keywords: Carcinoma ex pleomorphic adenoma; Eribulin; HER-2; Head and neck cancer; Pertuzumab; Salivary duct carcinoma; Trastuzumab.

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma* / drug therapy
Carcinoma* / pathology
Furans / therapeutic use
Humans
Ketones / therapeutic use
Neoplasm Metastasis
Salivary Ducts
Salivary Gland Neoplasms* / drug therapy
Salivary Gland Neoplasms* / pathology

Substances

Furans
Ketones
eribulin